These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 31974794)

  • 1. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.
    Yamashita S; Rizzo M; Su TC; Masuda D
    Metabolites; 2023 May; 13(5):. PubMed ID: 37233667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPPARM alpha: the Lazarus effect.
    Fruchart JC; Santos RD
    Curr Opin Lipidol; 2019 Dec; 30(6):419-427. PubMed ID: 31577610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
    Fruchart JC; Hermans MP; Fruchart-Najib J
    Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
    Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
    Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
    J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
    Fruchart JC; Santos RD; Aguilar-Salinas C; Aikawa M; Al Rasadi K; Amarenco P; Barter PJ; Ceska R; Corsini A; Després JP; Duriez P; Eckel RH; Ezhov MV; Farnier M; Ginsberg HN; Hermans MP; Ishibashi S; Karpe F; Kodama T; Koenig W; Krempf M; Lim S; Lorenzatti AJ; McPherson R; Nuñez-Cortes JM; Nordestgaard BG; Ogawa H; Packard CJ; Plutzky J; Ponte-Negretti CI; Pradhan A; Ray KK; Reiner Ž; Ridker PM; Ruscica M; Sadikot S; Shimano H; Sritara P; Stock JK; Su TC; Susekov AV; Tartar A; Taskinen MR; Tenenbaum A; Tokgözoğlu LS; Tomlinson B; Tybjærg-Hansen A; Valensi P; Vrablík M; Wahli W; Watts GF; Yamashita S; Yokote K; Zambon A; Libby P
    Cardiovasc Diabetol; 2019 Jun; 18(1):71. PubMed ID: 31164165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
    Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.
    Fruchart JC
    Cardiovasc Diabetol; 2017 Oct; 16(1):124. PubMed ID: 28978316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.
    Komatsu T; Miura T; Joko K; Sunohara D; Mochidome T; Kasai T; Ikeda U
    Intern Med; 2021 Sep; 60(17):2741-2748. PubMed ID: 33776008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
    Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
    Atherosclerosis; 2017 Jun; 261():144-152. PubMed ID: 28410749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
    Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
    Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
    Iitake C; Masuda D; Koseki M; Yamashita S
    Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists.
    Fruchart JC
    Cardiovasc Diabetol; 2013 May; 12():82. PubMed ID: 23721199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
    Ida S; Kaneko R; Murata K
    Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
    Fruchart JC; Hermans MP; Fruchart-Najib J; Kodama T
    Curr Atheroscler Rep; 2021 Jan; 23(1):3. PubMed ID: 33392801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
    Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
    Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
    Tanaka A; Nakamura T; Sato E; Chihara A; Node K
    CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.